echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Eli Lilly and Amgen reach cooperation on COVID-19 antibody therapy

    Eli Lilly and Amgen reach cooperation on COVID-19 antibody therapy

    • Last Update: 2020-10-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On Thursday, Lilly and Amjin announced a partnership for COVID-19 antibody therapy, which the two companies said in a statement would give them the ability to expand production if one or more of Lilly's antibody therapies are approved by regulators.
    antibody therapy works by identifying and locking in foreign invading viruses to prevent infection of healthy cells.
    The most promising regulatory approval for this collaboration is LY-CoV555, a powerful, neutral IgG1 monoclonal antibody against SARS-CoV-2 echithrin, primarily neutral antibodies collected in patients recovering from COVID-19, designed to neutralify viruses, prevent virus attachment and enter human cells, potentially prevent and treat CODVI-19.
    the ongoing randomized, double-blind, placebo-controlled Phase 2 study of LY-CoV-555 recruited about 800 subjects with mild to moderate symptoms and were treated with LY-CoV555 in outpatient clinics.
    a single injection of its experimental antibody, LY-CoV-555, could reduce hospitalization and emergency visits for patients in clinical trials with moderate C0VID-19, according to data from an interim trial released Wednesday by Lilly.
    specifically: 1.7 per cent of patients taking the drug were admitted to hospital and emergency care, compared with 6.0 per cent of patients taking placebo.
    LY-CoV555 is derived from Lilly's collaboration with AbCellera in developing antibody therapies to prevent and treat COVID-19.
    this partnership, in addition to the most promising LY-CoV-555( human trials were launched in August), Lilly has also started phase 2 trials by entering into a licensing agreement with Shanghai Junshi Bio to jointly develop LY-CoV016.
    , several companies, including Regeneratives and Biotechnology, are also testing Covid-19's antibody therapy.
    said separately Wednesday that it would discuss interim data with regulators around the world, including the FDA, about the possibility of obtaining authorization for emergency use of antibody therapies.
    addition to antibody therapy, Lilly is actively developing the potential of JAK inhibitor Olumiant to treat COVID-19.
    based on preliminary test data on ACTT-2 released recently.
    , Olumiant combined with Redsyve patients had a reduced mid-level recovery time by about one day compared to patients treated with Redsiway.
    if Olumiant succeeds, the drug would be the third early-approved COVID-19 therapy in the United States, after Veklury and recovery plasma therapy.
    has also been studying the potential of its own psoriasis drug Otezla for the treatment of COVID-19.
    addition, Amn has established a partnership with Adaptive Biotechnologies to develop antibody drugs that may prevent or treat COVID-19.
    () 
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.